SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to a significant drop following Phase 3 trial data, which, despite showing statistical significance in one analysis, was impacted by a high placebo response in another. The community is debating whether this drop is an overreaction, citing the company's cash runway, other pipeline products, and previous buyout rumors as reasons for potential recovery. Bullish investors believe long-term prospects remain strong, while others express concern over the trial results and potential implications for the company's future.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

$WEEDCOIN.X is trending as community members rally around the crypto's connection to cannabis culture and a shared vision of positivity. Advocates emphasize that $WEEDCOIN.X represents more than just a token; it's a movement towards freedom, community, and growth, aiming to bridge the gap between cannabis enthusiasts and the digital economy.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending as investors anticipate data from its nomlabofusp clinical development program for Friedreich's Ataxia, expected sometime this month. Community members are weighing the potential for positive results and a subsequent rise in stock price, while also considering the risk of negative outcomes given the high short interest and upcoming conference call to discuss updates. Some traders are noting unusual options activity, suggesting significant potential movement in either direction post-announcement.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement of approximately $44 million, leading to significant after-hours price movement. Community discussions revolve around the stock's small float, potential for a squeeze, and the impact of warrants associated with the deal. Some traders are optimistic about continued upward momentum, while others express concerns about potential dilution.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a Morgan Stanley downgrade, citing concerns about Alzheimer's trial risks, prescription trends, pricing pressures, and competition; however, the community is actively debating whether this downgrade is a strategic move to accumulate shares cheaply before positive news emerges, with some suggesting analysts are manipulating the stock for their benefit. While some express concern about the increased competition and potential margin squeeze, others emphasize the company's history of innovation and potential for long-term growth, particularly with its upcoming oral Wegovy and expansion into key markets like India.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals ($ENTA) is trending as investors anticipate topline results from its Phase 2b study of Zelicapavir for RSV, expected to be released soon. Bullish sentiment is building, with some traders hoping for a significant price increase if the data proves positive. The community is actively seeking insights and analysis to gauge the potential outcome of the study.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending due to the appointment of Barbara Humpton as the new CEO, effective October 1, 2025; the community is discussing her extensive experience and the company's strategic focus on becoming a leading supplier of rare earth minerals and magnets. Conversations also involve speculation around government deals and potential investment, along with options activity and price targets.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Merus is trending after Genmab announced its acquisition of the company for $97 per share, a deal valued at $8 billion, to gain access to a promising head and neck cancer drug. The community is buzzing about the buyout price and the strategic implications for Genmab as it aims to become a global biotech leader. Some traders are expressing regret for previously selling their shares while others are eyeing similar companies as potential takeover targets.

SuperVerse is a unified Web3 ecosystem connecting gaming, DeFi, and AI under a single interoperable protocol. Its native token, $SUPER, powers transactions, governance, and access to immersive games, AI-powered tools, and liquidity infrastructure such as Blackhole DEX. Designed for real utility across multiple chains, $SUPER enables staking, protocol buybacks, and sustainable yield while supporting a growing suite of decentralized applications.

SuperFarm

SuperFarm's crypto token, SUPER.X, is trending as the community anticipates a potential gaming run and a broader altcoin season, with some eyeing it as undervalued compared to Ethereum. Bullish sentiment is fueled by mentions from influencers and the anticipation of staking news, with community members actively discussing potential price targets and accumulation strategies.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to a massive volume spike and recent analyst upgrades, with community members speculating about a potential short squeeze given the low float. Discussions also revolve around the company's pipeline, particularly AVTX-009, and upcoming investor conferences. Some are comparing $AVTX to other low-float runners, while others discuss potential dilution concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Honeywell (HON) may grab attention on Monday as the industrial giant’s stock neared the worrying “death cross” pattern, a key technical signal that indicates that further pain may be on the cards, amid sticky bearishness among retail traders.The “death cross” is a technical indicator that forms when a stock’s 50-day moving average falls below its 200-day moving average, which could drive negative sentiment surrounding the shares. According to Koyfin data, Honeywell’s 50-day moving average stood at $217.70, perilously close to its 200-day moving average of $216.25, as of Friday’s close.<img src="https://news.stocktwits-cdn.com/koyfin_20250929_032849621_png_4aa2c6ae54.webp" alt="The chart shows two lines, signifying 50-day SMA and 200-day SMA, are close to converging. ">Over nearly a century, the death cross pattern in the broader markets has frequently appeared before severe bear markets, including those in 1929, 1938, 1974, and 2008. However, just the formation of this technical indicator does not always lead to further declines.Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/HON">Honeywell stock</a>, which has declined 5.5% this month, was ‘bearish’ at the time of writing, with the mood unchanged from a day, week, and month ago.<figure class="image"><img style="aspect-ratio:795/90;" src="https://news.stocktwits-cdn.com/HON_sept_29_JPG_7a156e5732.webp" alt="HON’s Sentiment Meter and Message Volume as of 02:42 a.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="795" height="90"><figcaption>HON’s Sentiment Meter and Message Volume as of 02:42 a.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>The recent weakness in Honeywell shares comes despite the company raising its annual adjusted earnings and revenue forecasts in July, following strong sales in its top revenue-generating aerospace division amid a spike in global demand in commercial aviation.Honeywell, which is also in the process of a three-way split by the second half of 2026, has raised its revenue forecast to between $40.8 billion and $41.3 billion, up from the previously projected range of $39.6 billion to $40.5 billion. However, the company’s margins continue to remain pressured by the wide swathe of tariffs imposed by the Trump administration.“This has to be one of the most painful stocks to watch,” one user wrote, adding that it's as though it's just waiting on “news.”<stembedurl>https://stocktwits.com/Gre05Ann/message/630182634</stembedurl>Honeywell is scheduled to post its third-quarter results on Oct. 23, where analysts expect the company to report $2.57 per share in earnings and $10.14 billion in revenue. The stock has fallen 8.3% this year, compared with the S&amp;P 500 SPDR ETF Trust’s 12.3% decline.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gold-surges-past-3-800-in-another-record-rally/chDMAJUR379">Gold Surges Past $3,800 In Another Record Rally — Peter Schiff Blames ‘Abject Failure’ Of Monetary And Fiscal Policies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A general exterior view of the logo sign on the Honeywell International Inc office building on January 15, 2024 in Basildon, United Kingdom. (Photo by John Keeble/Getty Images)

Honeywell Stock Flirts With ‘Death Cross’ Zone — Retail Traders Remain Bearish

It is a technical indicator that forms when a stock’s 50-day moving average falls below its 200-day moving average.

Equity

MARUY or HON: Which Is the Better Value Stock Right Now?

MARUY vs. HON: Which Stock Is the Better Value Option?

Honeywell's Industrial Automation Weakness Persists: What's the Road Ahead?

HON faces pressure in Industrial Automation, but strength in Aerospace and Building Automation offers balance.

Strength in Network Software Drives Roper: Can the Momentum Sustain?

ROP lifts its 2025 outlook as the Network Software and Application Software segments gain from GenAI, cross-sell and strong demand.

Will Strength in Aerospace Technologies Continue to Drive HON's Growth?

Honeywell's Aerospace Technologies segment posts strong Q2 growth, fueled by commercial aviation and defense demand.

Honeywell's Unit Prices Senior Notes Offering at $1B in Aggregate

HON's Solstice unit prices $1B senior notes due 2033, with proceeds tied to its upcoming spin-off and corporate needs.

Roper's Application Software Growth Picks Up: A Sign of More Upside?

ROP's Application Software unit gains traction with SaaS and GenAI-driven growth, prompting a higher 2025 revenue outlook.

Honeywell Unveils Ionic Modular All-in-One BESS for Industrial Use

HON unveils Ionic Modular All-in-One, a compact, flexible energy storage platform with advanced control and cybersecurity.

Honeywell International Inc. (HON) Stock Sinks As Market Gains: What You Should Know

The latest trading day saw Honeywell International Inc. (HON) settling at $211.7, representing a -1.17% change from its previous close.

QBTS in Focus Amid Quantum Launches, Competition With IBM, HON

QBTS stock price likely to rise as the company launches Advantage2, tackles AI and eyes 100K-qubit system amid IBM and Honeywell competition.

Honeywell International, Inc. is a software industrial company, which offers industry specific solutions to aerospace and automotive products and services. It operates through the following business segments: Aerospace Technologies, Industrial Automation, Building Automation, Energy and Sustainability Solutions, and Corporate and All Other. The company was founded by Albert M. Butz in 1906 and is headquartered in Charlotte, NC.

Honeywell International Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

HON
Honeywell International Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HON News

HON Honeywell International Inc